3-氨基-6-苯基-4-(三氟甲基)噻吩并[2,3-b]吡啶-2-羧酸 | 104960-56-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-氨基-6-苯基-4-(三氟甲基)噻吩并[2,3-b]吡啶-2-羧酸
• 英文名称: 3-amino-2-carboxy-4-trifluoromethyl-6-phenylthieno<2,3-b>pyridine
• 英文别名: 3-Amino-6-phenyl-4-(trifluoromethyl)thieno[2,3-b]pyridine-2-carboxylic acid
• CAS: 104960-56-7
• 化学式: C₁₅H₉F₃N₂O₂S
• mdl: MFCD00398797
• 分子量: 338.31
• InChiKey: MKXSKSYKJNXBGH-UHFFFAOYSA-N

物化性质

• 熔点：
  159 °C

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.066
• 拓扑面积：
  104
• 氢给体数：
  2
• 氢受体数：
  8

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  3-氨基-6-苯基-4-(三氟甲基)噻吩并[2,3-b]吡啶-2-羧酸 在 磷酸 作用下， 反应 6.0h， 以78%的产率得到3-amino-4-trifluoromethyl-6-phenylthieno<2,3-b>pyridine
  参考文献：
  名称：

  Rodinovskaya, L. A.; Sharanin, Yu. A.; Litvinov, V. P., Journal of Organic Chemistry USSR (English Translation), 1985, vol. 21, # 11, p. 2230 - 2235

  摘要：

  DOI：
• 作为产物：
  描述：

  苯甲酰三氟丙酮 在 氢氧化钾 、 sodium ethanolate 、 三乙胺 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 26.33h， 生成 3-氨基-6-苯基-4-(三氟甲基)噻吩并[2,3-b]吡啶-2-羧酸
  参考文献：
  名称：

  Rodinovskaya, L. A.; Sharanin, Yu. A.; Litvinov, V. P., Journal of Organic Chemistry USSR (English Translation), 1985, vol. 21, # 11, p. 2230 - 2235

  摘要：

  DOI：

文献信息

• Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections
  申请人：Siga Technologies, Inc.

  公开号：US20130129677A1

  公开（公告）日：2013-05-23

  Methods and pharmaceutical compositions for treating viral infections, by administering certain thienopyridine derivative compounds in therapeutically effective amounts are disclosed. Methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment of viral infections such as caused by flavivirus is disclosed, i.e., including but not limited to, Dengue virus, West Nile virus, yellow fever virus, Japanese encephalitis virus, and tick-borne encephalitis virus.

  本发明揭示了使用某些噻唑吡啶衍生物化合物以治疗病毒感染的方法和制药组合物，通过以治疗有效剂量给药。同时还揭示了使用这些化合物和制药组合物的方法。具体地，揭示了治疗由黄热病毒、日本脑炎病毒、西尼罗河病毒、登革热病毒和蜱媒脑炎病毒等引起的病毒感染的方法。
• THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS
  申请人：Siga Technologies, Inc.

  公开号：US20160152635A1

  公开（公告）日：2016-06-02

  Methods and pharmaceutical compositions for treating viral infections, by administering certain thienopyridine derivative compounds in therapeutically effective amounts are disclosed. Methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by flavivirus is disclosed, i.e., including but not limited to, Dengue virus, West Nile virus, yellow fever virus, Japanese encephalitis virus, and tick-borne encephalitis virus.

  本发明公开了通过以治疗有效剂量给予某些噻唑吡啶衍生物化合物来治疗病毒感染的方法和制药组合物。本发明还公开了使用这些化合物和其制药组合物的方法。具体而言，本发明公开了治疗和预防由黄热病毒、日本脑炎病毒、蜱传脑炎病毒等引起的病毒感染的方法，但不限于此。
• RODINOVSKAYA, L. A.;SHARANIN, YU. A.;LITVINOV, V. P.;SHESTOPALOV, A. M.;P+, ZH. ORGAN. XIMII, 1985, 21, N 11, 2439-2444
  作者：RODINOVSKAYA, L. A.、SHARANIN, YU. A.、LITVINOV, V. P.、SHESTOPALOV, A. M.、P+

  DOI：——

  日期：——
• US9301949B2
  申请人：——

  公开号：US9301949B2

  公开（公告）日：2016-04-05
• Discovery and structure–activity relationships study of novel thieno[2,3-b]pyridine analogues as hepatitis C virus inhibitors
  作者：Ning-Yu Wang、Wei-Qiong Zuo、Ying Xu、Chao Gao、Xiu-Xiu Zeng、Li-Dan Zhang、Xin-Yu You、Cui-Ting Peng、Yang Shen、Sheng-Yong Yang、Yu-Quan Wei、Luo-Ting Yu

  DOI：10.1016/j.bmcl.2014.01.075

  日期：2014.3

  Current treatment for hepatitis C is barely satisfactory, there is an urgent need to develop novel agents for combating hepatitis C virus infection. This study discovered a new class of thieno[ 2,3-b] pyridine derivatives as HCV inhibitors. First, a hit compound characterized by a thienopyridine core was identified in a cell-based screening of our privileged small molecule library. And then, structure activity relationship study of the hit compound led to the discovery of several potent compounds without obvious cytotoxicity in vitro (12c, EC50 = 3.3 mu M, SI > 30.3, 12b, EC50 = 3.5 mu M, SI > 28.6, 10l, EC50 = 3.9 mu M, SI > 25.6, 12o, EC50 = 4.5 mu M, SI > 22.2, respectively). Although the mechanism of them had not been clearly elucidated, our preliminary optimization of this class of compounds had provided us a start point to develop new anti-HCV agents. (C) 2014 Elsevier Ltd. All rights reserved.